Stay updated on BGB324 in Recurrent Glioblastoma Surgery Clinical Trial
Sign up to get notified when there's something new on the BGB324 in Recurrent Glioblastoma Surgery Clinical Trial page.

Latest updates to the BGB324 in Recurrent Glioblastoma Surgery Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe webpage has undergone significant updates, including the removal of detailed information about a phase I trial for the AXL inhibitor BGB324 in treating recurrent glioblastoma, while adding new identifiers and collaborators related to the study.SummaryDifference44%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check88 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to BGB324 in Recurrent Glioblastoma Surgery Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BGB324 in Recurrent Glioblastoma Surgery Clinical Trial page.